GSK
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.06 | 10 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| phase 2 | ×1.17 | 5 |
| preclinical | ×0.72 | 5 |
| approved | ×1.14 | 3 |
Strategy profile
Based on 15 disclosed transactions, GSK concentrates its licensing activity in Oncology, InfectiousDisease, and Neurology. GSK pays a 1.03x premium over market median, with the strongest premiums in Oncology (1.06x). Their most common deal structure is Acquisition, with an average disclosed value of $2.4B. Most recent activity: 2025.
Premium by therapeutic area
How GSK pays relative to peer medians in each TA
Pipeline coverage & gaps
GSK has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| AcquisitionPrimary | 5 | $1.6B | $1.6B |
| CollaborationPrimary | 5 | $393M | $2.6B |
| License | 3 | $343M | $4.9B |
| Co Development | 2 | $18M | $332M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2025 | multi-indication | Hengrui Pharma | multi-indication | phase_1 | $500M | $12.5B |
| 2025 | gastrointestinal stromal tumor | IDRx | gastrointestinal stromal tumor | phase_2 | $1.0B | $1.0B |
| 2025 | CD19-tinib | Vor Biopharma | Cholangiocarcinoma | discovery | $19M | $323M |
| 2025 | parkinsons | Vesalius Therapeutics | parkinsons | preclinical | $80M | $650M |
| 2025 | HER2 | BioNTech | GBM | phase_3 | $218M | $1.1B |
| 2024 | lupus | Chimagen Biosciences | lupus | preclinical | $550M | $550M |
| 2024 | HER3-tinib | Chugai Pharmaceutical | Endometrial | discovery | $18M | $341M |
| 2024 | PI3K | Arcus Biosciences | Endometrial | phase_3 | $939M | $7.8B |
| 2023 | asthma | Aiolos Bio | asthma | phase_1 | $1.0B | $1.4B |
| 2023 | JNJ-3989 (HBV siRNA) | Janssen/Arrowhead | Chronic HBV functional cure | phase_2 | — | $1.0B |
| 2023 | HS-20089 | Hansoh Pharma | Breast, Ovarian, Endometrial | phase_1 | $185M | $1.3B |
| 2023 | amrBacterial | Affinivax | amrBacterial | phase_2 | $3.3B | $3.3B |
| 2022 | Momelotinib (Ojjaara) | Sierra Oncology | Myelofibrosis | phase_3 | $1.9B | $1.9B |
| 2022 | solid_tumors | Duality Biologics | solid_tumors | preclinical | $30M | $1.0B |
| 2021 | AL001 (latozinemab) + AL101 | Alector | Frontotemporal Dementia, Alzheimer's Disease | phase_2 | $700M | $2.2B |
How this is computed
For each GSK deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 15 disclosed deal premiums vs. peer medians. Raw premium 1.035, clamped to [0.7, 1.5].